indication

Psychotic Disorders

Competitive landscape projected to Case-management’s launch window

as of 2026-07-01
Competitive set
12
8 approved · 4 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
55 events
2020
2024
2028
2032
2036
2040
2044
2048
today
Case-management launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 434 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 416 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 412 trials
OwnerAstraZeneca
Protection—
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 412 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 46 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 35 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
Clozapine
US-approved 1989 · Clozaril
Phase 42 trials
OwnerShanghai Mental Health Center
Protection2028
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 32 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Sarcosine
Pipeline · Phase 2
Phase 23 trials
OwnerChina Medical University Hospital
Protection—
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 41 trial
OwnerSanofi
Protection2038
drugCompleted
Perphenazine
Pipeline · Phase 3
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugNot Yet Recruiting
Cannabidiol
Pipeline · Phase 3
Phase 31 trial
OwnerCentral Institute of Mental Health, Mannheim
Protection—

Market size

prevalence as a range, not a number